Biohaven (BHVN) vs Zenas BioPharma (ZBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Zenas BioPharma (ZBIO) has outperformed Biohaven (BHVN) over the past year, losing 1.8% versus a loss of 29.9%. Biohaven is the larger company by market cap ($1.82 billion vs $1.78 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BHVN | ZBIO |
|---|---|---|
| Share price | $12.08 | $27.26 |
| Market cap | $1.82B | $1.78B |
| 1-day change | +1.26% | +3.89% |
| YTD return | +7.00% | -24.92% |
| 1-year return | -29.89% | -1.80% |
| EPS (TTM) | $-4.62 | $-9.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $10.00M |
| Revenue growth (YoY) | — | +100.00% |
| Net income (latest FY) | $-738.82M | $-377.74M |
| Operating margin | — | -3830.57% |
| Net margin | — | -3777.37% |
| 52-week high | $18.57 | $44.60 |
| 52-week low | $7.48 | $13.50 |
| Distance from 52-week high | -34.93% | -38.88% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +76.08% | +75.64% |
| Average volume | 2.63M | 733.34K |
| Shares outstanding | 151.04M | 65.18M |
| Employees | 274 | 167 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZBIO has outperformed BHVN by 28.1 percentage points over the past year.
- The two companies sit in different sectors: Biohaven in Healthcare and Zenas BioPharma in Health Care.
About Biohaven
BHVN stock →Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.
Healthcare · Biotechnology · 274 employees
About Zenas BioPharma
ZBIO stock →Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.
Health Care · Biotechnology: Pharmaceutical Preparations · 167 employees
BHVN vs ZBIO FAQ
Which is bigger, Biohaven or Zenas BioPharma?
Biohaven (BHVN) is larger, with a market capitalization of $1.82B compared with $1.78B for Zenas BioPharma (ZBIO).
Which stock has performed better over the past year, BHVN or ZBIO?
ZBIO returned -1.80% over the past 12 months, compared with -29.89% for BHVN (price return, excluding dividends). Past performance does not predict future results.
Are Biohaven and Zenas BioPharma in the same industry?
No. Biohaven is in the Healthcare sector, while Zenas BioPharma is in Health Care.